Discloses the consolidated results and outlook for the FY2026 ending June. Includes trends in revenue, operating income, ordinary income, and net income attributable to owners of the parent, along with segment composition of sales, major cost drivers, and ongoing strategy to strengthen Healthcare Solutions and develop new areas.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6090","jir_company_name":"Human Metabolomics Technologies Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-20","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/6090-20260820-01.pdf","jir_short_summary":"Discloses the consolidated results and outlook for the FY2026 ending June. Includes trends in revenue, operating income, ordinary income, and net income attributable to owners of the parent, along with segment composition of sales, major cost drivers, and ongoing strategy to strengthen Healthcare Solutions and develop new areas.","jir_summary":"### Section heading\nOverview of the consolidated results for the fiscal year ending June 2026 and the composition of segment sales. Revenue is 1,421 million yen, operating income 209 million yen, and ordinary income 206 million yen. Key factors include expansion of Healthcare Solutions, trends in manufacturing costs and selling, general and administrative expenses, and contributions by region and business. Provides breakdown of segment sales and profits, analysis of major cost drivers, and the underlying assumptions that will influence the outlook for the FY2027 results.\n\n### Section 2 heading\nFuture strategy and initiatives to improve profitability. Emphasis on investment in research and development for new areas, productivity gains through digitalization, new menu developments to enhance customer satisfaction, achieving profitability in Healthcare Solutions and controlling cost of goods sold to improve margins. The medium-term plan outlines growth foundations for 2024-2026, strengthening technological competitiveness, and optimizing capital allocation.","jir_financial_highlights":"Sales revenue: 1,421 (YoY unknown)\nOperating income: 209 (YoY unknown)\nOrdinary income: 206 (YoY unknown)\nNet income attributable to owners of the parent: Unknown (Unknown)","jir_category":"","jir_hashtags":"#Human Metabolomics Technologies, #Earnings, #BusinessStrategy, #SelfDataAnalysis","jir_key_figures":"Sales: 1,421 (Unit: million yen) \nOperating income: 209 (Unit: million yen) \nOrdinary income: 206 (Unit: million yen) ","jir_meta_title":"\u3010Human Metabolomics Technologies\u3011FY2026 June Earnings\uff5cSales 1,421 million yen, Operating income 209 million yen","jir_meta_description":"Summary of Human Metabolomics Technologies' earnings for the fiscal year ending June 2026. Details on revenue, operating profit, segment breakdown, and mid-term strategies and growth initiatives.","jir_og_title":"\u3010Human Metabolomics Technologies\u3011FY2026 June Earnings (Summary)","jir_og_description":"Key points of consolidated results for FY2026 and the medium-term plan. Summary of revenue, profit trends, segment movements, and future growth strategies.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-06\\\",\\\"2026-06\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[1455,1421]}]}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-06\\\",\\\"2026-06\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating income\\\",\\\"data\\\":[249,209]}]}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Profit Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025-06\\\",\\\"2026-06\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Ordinary income margin\\\",\\\"data\\\":[(206\/1421)*100,(206\/1421)*100]}]}}\"}]","ir_related_company":60381,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-105743","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n